References
- 1. Zhou, J., Xu., Y., Liu, J., Feng, L., Yu, J., Chen, D., 2024: Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol., 93, 102693. DOI: 10.1016/j. canep.2024.102693
- 2. Boyle, B. J., Shanks, T., Croom, S. M., Smith, R. J., Miller, L., Loaring, N., Heymans, C., 2000: The 2dF QSO redshift survey – I. The optical luminosity function of quasi-stellar objects. Mon. Not. the Royal Astronom. Soc., 317, 4, 1014–1022. DOI: 10.1046/j.1365-8711.2000.03730.x
- 3. Lyerly, A. D., 2010: Marking the fine line: ethics and the regulation of innovative technologies in human reproduction. Minnesota J. Law, Sci. & Tech., 11, 2, 685–712. https://scholarship.law.umn.edu/mjlst/vol11/iss2/10?utm_source=scholarship.law.umn.edu%2Fmjlst%2Fvol11%2Fiss2%2F10&utm_medium=PDF&utm_campaign=PDFCoverPages
- 4. Soerjomataram, I., Lortet-Tieulent, J., Parkin, D. M., Ferlay, J., Mathers, C., Forman, D., Bray, F., 2012: Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. The Lancet, 380, 9856, 1840–1850. DOI: 10.1016/s0140-6736(12)60919-2
- 5. Feely, R. A., Alin, S. R., Newton, J., Sabine, C. L., Warner, M., Devol, A., Krembs, C., Maloy, C., 2010: The combined effects of ocean acidification, mixing, and respiration on pH and carbonate saturation in an urbanized estuary. Estuar Coast & Shelf Sci., 88, 4, 442–449. DOI: 10.1016/j. ecss.2010.05.004
- 6. Ferlay, J., Randi, G., Bosetti, C., Levi, F., Negri, E., Boyle, P., La Vecchia, C., 2008: Declining mortality from bladder cancer in Europe. BJU Int., 101, 1, 11–19. DOI: 10.1111/j.1464-410x.2007.07239.x
- 7. Sylla, B. S., Wild, C. P., 2011: A million africans a year dying from cancer by 2030: What can cancer research and control offer to the continent? Int. J. Cancer, 130, 2, 245–250. DOI: 10.1002/ijc.26333
- 8. International Agency for Research on Cancer (IARC), 2020
- 9. Dix, D., Cohen, P., Flannery, J., 1980: On the role of aging in cancer incidence. J. Theor. Biol., 83, 1, 163–173. DOI: 10.1016/0022-5193(80)90377-x
- 10. Simmons, D. L., Botting, R. M., Hla, T., 2004: Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev., 56, 3, 387–437. DOI: 10.1124/pr.56.3.3
- 11. Bayer, G., 2015: Matindale: The complete drug reference. 38th ed. Aust. Prescr., 38, 2, 59. DOI: 10.18773/austprescr.2015.023
- 12. Bhattacharya, S., Ghosh, R., Maiti, S., Khan, G. A., Sinha, A. K., 2013: The activation by glucose of liver membrane nitric oxide synthase in the synthesis and translocation of glucose transporter-4 in the production of insulin in the mice hepatocytes. PloS One, 8, 12, e81935. DOI: 10.1371/journal.pone.0081935
- 13. Saganuwan, S. A., Orinya, O. A. 2016: Toxico-neurological effects of piroxicam in monogastric animals. J. Exper. Neurosci., 10, 121–128. DOI: 10.4137/JEN.S40144
- 14. Saganuwan, S. A., 2016: Physicochemical and structure-activity properties of piroxicam—a mini review. Comp. Clin. Pathol., 25, 941–945. DOI: 10.1007/s00580-016-2284-3
- 15. Knapp, J. R., Freetly, H. C., Reis, B. L., Calvert, C. C., Baldwin, R. L., 1992: Effects of somatotropin and substrates on patterns of liver metabolism in lactating dairy cattle. J. Dairy Sci., 75, 4, 1025–1035. DOI: 10.3168/jds.s0022-0302(92)77846-1
- 16. Xin, B., Yokoyama, Y., Shigeto, T., Mizunuma, H., 2007: Anti-tumor effect of non-steroidal anti-inflammatory drugs on human ovarian cancers. Pathol. Oncol. Res., 13, 4, 365–369. DOI: 10.1007/bf02940318
- 17. Earnet, D. L., Hixson, L. J., Alberts, D. S., 1992: Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. J. Cell. Biochem. Suppl., 50, S 16l, 156–166. DOI: 10.1002/jcb.240501330
- 18. Lindsey, P. A., Nyirenda, V. R., Barnes, J. I., Becker, M. S., McRobb, R., Tambling, C. J., 2014: Underperformance of African protected area networks and the case for new conservation models: insights from Zambia. PLoS One, 9, 5, e94109. DOI: 10.1371/journal.pone.0094109
- 19. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2004: Tobacco smoke and involuntary smoking. Lyon (FR). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans., 83, 33–1187. https://www.ncbi.nlm.nih.gov/books/NBK316407/
- 20. Collin, G., Höke, H., Talbiersky, J., 2006: “Anthracene” in Ullmann’s Encyclopedia of Industrial Chemistry, Wiley-VCH, Weinheim. https://doi.org/10.1002/14356007.a02_343.pub2
- 21. Verschueren, K., Marcoen, A., Schoefs, V., 1996: The internal working model of the self, attachment, and competence in five-year-olds. Child Dev., 67, 5, 2493–2511. PMID: 9022252.
- 22. Saini, R. K., Chouhan, R., Bagri, L. P., Bajpai, A. K., 2012: Strategies of targeting tumors and cancers. J. Cancer Res. Updates, 1, 129–152.
- 23. OECD 2015: OECD guidelines on corporate governance of state-owned enterprises. 2015 edition, OECD Publishing, Paris: 1–80. http://dx.doi.org/10.1787/9789264244160-en
- 24. Hodgson, E., 2004: A Textbook of Modern Toxicology 3rd ed., Wiley-InterScience, A. John Wiley & Sons, Inc., Publication, 557.
- 25. Kishi, S., Yokohira, M., Yamakawa, K., Saoo, K., Im-aida, K., 2024: Significance of the progesterone receptor and epidermal growth factor receptor, but not the estrogen receptor, in chemically induced lung carcinogenesis in female A/J mice. Oncol. Lett., 8, 6, 2379–2386. DOI: 10.3892/ol.2014.2559
- 26. Oluchi, O. M., Chukwuebuka, N. H., Orbunde, D. K., Daniel, A. W., Aondohemba, U. V., Ieren, I. I., Bosha, J. A., Saganuwan, S. A., Azubuike, O. P., 2024: Benz[a]anthracene-induced pulmonary toxicity in Rattus norvegicus. J. Toxicity Envir. Health Sci., 16, 1, 1–12. DOI: 10.5897/JTEHS2023.0517
- 27. Saganuwan, S. A., Onyeyili, P. A., 2016: The paradox of human equivalent dose formula: a canonical case study of Abrus precatorius aqueous leaf extract in monogastric animals. Mac. Vet. Rev., 39, 1, 23–32. https://macvetrev.mk/LoadAbstract?DOI=10.1515_macvetrev_2015_0061
- 28. Thermo Fisher Scientific, 2024: Carboplatin In: Safety Data Sheet, Health, Safety and Environment Department, 1–8.
- 29. Davis, R. K., Stevenson, G. T., Busch, K. A., 1956: Tumor incidence in normal Sprague-Dawley female rats. Cancer Res., 16, 3, 194–197. PMID: 13304860.
- 30. Nagabhushanam, M. V., Sudha, R. A., 2010: Evaluation of phamacokinetic parameters of solid dispersions of piroxicam, 333–343. Inkollu: DCRM pharmacy College, Department of Pharmaceutics. [Google Scholar].
- 31. Akogwu, E., I., Saganuwan, S. A., Onyeyili, P. A., 2017: Comparative pharmacokinetics of piroxicam in male and female West African Dwarf goats. Cog. Food & Agric., 3, 1, 1–8. DOI: 10.1080/23311932.2017.1294444
- 32. Barros, A. C. S. D, Muranaka, E. N. K., Mori, L. J., Pelizon, C. H. T., Iriya, K., Giocondo, G., Pinotti, J. A. 2004: Induction of experimental mammary carcinogenesis in rats with 7, 12-methyl-benz(a)anthracene. Rev. Hosp. Clin., 59, 5, 257–261. DOI: 10.1590/s0041-87812004000500006
- 33. Saganuwan, S. A., 2021: Modified formulas for calculation of encephalization: quotient in dogs. BMC Res. Notes, 14, 1, 223. DOI: 10.1186/s13104-021-05638-0
- 34. Saganuwan, S. A., 2018: Mathematical determination of some oncological parameters and their therapeutic applications in dogs. Comp. Clin. Pathol., 28, 1025–1030. DOI: 10.1007/s00580-018-2874-3
- 35. Saganuwan, S. A., 2012: Principles of Pharmacological Calculations, 1st ed., Ahmadu Bello University Press.
- 36. Daniel, W. W., Cross, C. L., 2010: Biostatistics: Basic Concept and Methodology for Health Sciences, 9th edn., Wiley, New Delhi, 777.
- 37. Abatan, M. O., Lattef, I., Taiwo, V., O., 2006: Toxic effects of non-steroidal anti-inflammatory agents in rats. Afr. J. Biomed. Res., 9, 219–223. DOI: 10.4314/ajbr.v9i3.48909
- 38. Stark, A. A., 1980: Mutagenicity and carcinogenicity of mycotoxins: DNA binding as a possible mode of action. Ann. Rev. Microbiol., 34, 235–262. DOI: 10.1146/annurev. mi.34.100180.001315
- 39. Gamrat-Zmuda, A., Minasyan, M., Wysocki, P. J., Hubalewska-Dydejezyk, A., Gilis-Januszeuskal, A., 2025: Ectopic cushing’s syndrome in advanced small-cell lung cancer (SCLC): clinical challenges and therapeutic insights. Cancer (Basel), 17, 10, 1611. https://doi.org/10.3390/cancers17101611
- 40. Saganuwan, S. A., 2023: Ameliorative effects of piroxicam on perchloric acid-induced thyroid gland hormones disruption in male rats. J. King Saud Univ.-Sci., 35, 2, 102661. DOI: 10.1016/j.jksus.2023.102661
- 41. Schmidt-Nielsen, K., 1964: Desert animals: physiological problems of heat and water. Claredon press, Oxford.
- 42. Alamdari, S. G., Mohammadzadeh, R., Amini, M., Najafi, S., Baradaran, B., Mahdavi, S. Z. B., Yari, A., Mokhtarzadeh, A. A., 2025: Improvement of carboplatin chemosensitivity in lung cancer cells by siRNA-mediated downregulation of DLGAP1-AS2 expression. Sci. Rep., 15, 7971. DOI: 10.1038/s41598-025-87649-6
- 43. Samani, A., Bennett, R., Eremeishvili, K., Kalofonou, F., Whear, S., Montes, A., et al., 2022: Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers. ESMO Open, 7, 2, 100401. DOI: 10.1016/j.esmoop.2022.100401
- 44. Knapp, D. W., Chan, T. C., Kuczek, T., Reagan, W. J., Park, B., 1995: Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am. J. Vet. Res., 56, 6, 801–5. PMID: 7653891.
- 45. Malfassi, L., Fidanzio, F., Sala, M., Marcarini, S., Mazza, G., Carrara, N., et al., 2021: A combined protocol with piroxicam, chemotherapy, and whole pelvic irradiation with simultaneous boost volumetric modulated arc radiotherapy for muscle-invasive canine urinary transitional cell carcinoma: First clinical experience. J. Vet. Med. Sci., 83, 4, 695–704. DOI: 10.1292/jvms.19-0662
- 46. Chang, M. T., Penson, A., Desai, N. B., Socci, N. D., Shen, R., Seshan, V. E., et al., 2018: Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clin. Cancer Res., 24, 8, 1965–1973. DOI: 10.1158/1078-0432.CCR-17-2655
- 47. Pollard, M., Luckert, P. H., Schmidt, M. A., 1983: The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat. Cancer Lett., 21, 1, 57–61. DOI: 10.1016/0304-3835(83)90082-4
- 48. Menter, D. G., DuBois, R. N., 2012: Prostaglandins in cancer cell adhesion, migration, and invasion. Int. J. Cell Biol., 723419. DOI: 10.1155/2012/723419
- 49. Lazer, E. S., Miao, C. K., Cywin, C. L., Sorcek, R., Wong, H.-C., Meng, Z., et al., 1997: Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity. J. Med. Chem., 40, 6, 980–989. DOI: 10.1021/jm9607010
- 50. Saganuwan, S. A., Egworrow, O. E., Ode, A. J., 2023: Effects of diminazene aceturate on flip-flop plasma pharmacokinetics of piroxicam in dogs. J. King Saud Univ.-Sci., 35, 16, 102914. DOI: 10.1016/j.jksus.2023.102914
- 51. Soni, M. G, 2014: Benz[a]anthracene In: Gray, J. P. and Hall, G. J. (eds) of Toxicology, 2nd ed., 413–414.
- 52. Kishi, K., Homma, S., Kurosaki, A., Motoi, N., Kohno, T., Nakata, K., Yoshimura, K., 2004: Small lung tumors with the size of 1 cm or less in diameter: clinical, radiological, and histopathological characteristics. Lung cancer, 44, 1, 43–51. DOI: 10.1016/j.lungcan.2003.09.024
- 53. Hong, J. H., Park, S., Kim, H., Goo, J. M., Park, I. K., Kang, C. H., et al., 2021: Volume and mass doubling time of time lung adenocarcinoma according to WHO histologic classification. Korean J. Radiol., 22, 3, 464–-475. DOI: 10.3348/kjr.2020.0592
- 54. De Sousa, G. F., Wlodarczyk, S. R., Monteiro, G., 2014: Carboplatin: molecular mechanisms of action associated with chemoresistance. Braz. J. Pharm. Sci., 50, 4, 1–9. DOI: 10.1590/S1984-82502014000400004
- 55. Recnik, L.-M., Cantelli, C., Fersing, C., Gongora, C., Pouget, J.-P., Lisowski, V., 2020: Synthesis and in vitro antitumour activity of carboplatin analogues containing functional handles compatible for conjugation to drug delivery systems. Bioorg. Med. Chem. Lett., 30, 22, 127527. DOI: 10.1016/j.bmcl.2020.127527
- 56. Vermorken, J. B., ten Bokkel Huinink, W. W., Eisenhauer, E. A., Favalli, G., Belpomme, D., Conte, P. F., Kaye, S. B., 1993: Advanced ovarian cancer. Carboplatin versus cisplatin. Ann Oncol., 4, 4, 41–48. PMID: 8312200.
- 57. Miyano, K., Shiraishi, S., Minami, K., Sudo, Y., Suzuki, M. M., Yokoyama, T., et al., 2019: Carboplatin enhances the activity of human transient receptor potential ankyrin 1 through the cyclic AMP-protein kinase A-A-kinase anchoring protein (AKAP) pathways. Int. J. Mol. Sci., 20, 13, 3271. DOI: 10.3390/ijms20133271
- 58. Millen, G. C., Lawford, A., Duncan, C., Jenkinson, H., Veal, G. J., Barnett, S., 2024: Utility of carboplatin therapeutic drug monitoring for the treatment of neonate and infant retinoblastoma patients in the United Kingdom. Br. J. Cancer, 131, 3, 491–497. DOI: 10.1038/s41416-024-02728-1
- 59. Mo, J., Eggers, P. K., Chen, X., Ahamed, M. R. H., Becker, T., Lim, L. Y., Raston, C. L., 2015: Shear induced carboplatin binding within the cavity of a phospholipid mimic for increased anticancer efficacy. Sci. Rep., 5, 10414, 1–9. DOI: 10.1038/srep10414
- 60. Faulkner, D., Meldrum, C., 2012: Tumour markers. Aust. Prescr., 35, 4, 125–128. DOI: 10.18773/austprescr.2012.052
- 61. Kumar, K., Jain, P., Sinha, A., Singh, K. K., Sharma, H. P., 2014: Clinical significance of tumor markers. Am. J. Phytomed. Clin. Ther., 2, 8, 1005–1015.
- 62. Flectcher, R. H., 1986: Carcinoembryonic antigen. Ann. Intern. Med., 104, 1, 66–73. DOI: 10.7326/0003-4819-104-1-66
- 63. Hansen, M., 1991: Serum tumour markers in lung cancer. Scand. J. Clin. Lab. Invest., 51, 206, 93–101.
- 64. Ferrigno, D., Buccheri, G., 1995: Clinical applications of serum markers for lung cancer. Respir. Med., 89, 9, 587–597. DOI: 10.1016/0954-6111(95)90225-2
- 65. Tiep, B., Carter, R., Zachariah, F., Williams, A. C., Horak, D., Barnet, M., Dunham, R., 2013: Oxygen for the end-of-life lung cancer care: managing dyspnea and hypoxemia. Expert Rev. Respir. Med., 7, 5, 479–490. DOI: 10.1586/17476348.2013.816565
- 66. Igarashi, H., Fukushi, M., Nago, N., 2020: Oxygen use and survival in patients with advanced cancer and low oxygen saturation in home care: a preliminary retrospective cohort study. BMC Palliat. Care, 19, 3. DOI: 10.1186/s12904-019-0511-9
- 67. Jones, L. W., Watson, D., Herndon, J. E., Eves, N. D., Haithcock, B. E., Loewen, G., Kohman, L., 2010: Peak Oxygen consumption and long-term all-cause mortality in non-small cell lung cancer. Cancer, 116, 20, 4825–4832. DOI: 10.1002/cncr.25396
- 68. Licker, M., Schnyder, J.-M., Frey, J.-G., Diaper, J., Cartier, V., Inan, C., et al., 2011: Impact of aerobic exercise capacity and procedure-related factors in lung cancer surgery. Eur. Respir. J., 37, 5, 1189–1198. DOI: 10.1183/09031936.00069910
- 69. Franklin, J., Serra-Diaz, J. M., Syphard, A. D., Regan, H. M., 2016: Global change and terrestrial plant community dynamics. Proc. Natl. Acad. Sci. USA, 113, 14, 3725–3734. DOI: 10.1073/pnas.1519911113
- 70. U.S. Environmental Protection Agency guidelines for carcinogen risk assessment, 1986.